Financial Data and Key Metrics Changes - The company reported organic sales growth of 3% for 2025, which was below expectations due to a slowdown in the U.S. market and a weaker cold and flu season [8][9] - Gross margin improved by 220 basis points, contributing to a high single-digit operating growth at constant currency [10][44] - The company anticipates organic sales growth guidance of 3%-5% for 2026, indicating a potential sequential acceleration [6][11] Business Line Data and Key Metrics Changes - The U.S. market experienced a decline of approximately 0.5%, while APAC, EMEA, and LATAM grew in the mid-single digits [8][9] - Oral health business showed strong performance, helping to offset declines in the cold and flu category [9][20] - The company plans to focus on driving category growth through investments in advertising and promotion (A&P) and innovation [10][12] Market Data and Key Metrics Changes - Emerging markets, particularly India and China, are expected to contribute significantly to growth, with India showing double-digit growth and strong performance in oral health [29][30] - The company noted a slowdown in LATAM, particularly in Q4, due to challenging macroeconomic conditions [30][31] - E-commerce is growing aggressively in China, with significant contributions from platforms like Douyin [29][30] Company Strategy and Development Direction - The company has restructured its leadership to enhance agility and drive growth, including the creation of a Chief Growth Officer role and six operating units [15][18] - Focus on innovation and commercial execution is emphasized to improve competitiveness in the U.S. market [15][19] - The company aims to leverage its strengths in oral health and expand its reach in emerging markets [12][29] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertain market conditions but expressed confidence in returning to the medium-term growth target of 4%-6% [11][68] - The company is focused on addressing consumer needs and driving category growth despite current challenges [52][53] - Management highlighted the importance of the cold and flu category for overall consumer health and its role in securing shelf space [56][57] Other Important Information - The company has increased A&P investment by over 7% compared to the previous year, with a significant portion allocated to oral health and emerging markets [35][75] - The productivity program has been successful, allowing for flexibility in investments for growth [44][46] Q&A Session Summary Question: What are the main drivers behind the organic sales growth guidance of 3%-5% for 2026? - Management indicated that the guidance reflects expected market improvements and a focus on driving category growth through investments and innovation [6][11] Question: Can you discuss the new reorganization and its impact on growth in the U.S.? - The reorganization aims to unlock growth and agility, with a focus on commercial execution and category strategies [15][18] Question: How is the performance in emerging markets, and what are the growth drivers? - Emerging markets are performing well, particularly in India and China, with a focus on volume growth and expanding reach [29][30] Question: How does the company plan to balance top-line performance with margin improvement? - Management emphasized the importance of investing in the right areas to drive sustainable growth while improving margins [35][36] Question: What is the outlook for the cold and flu business and its importance? - The cold and flu category is crucial for consumer health and shelf space, with management confident in its long-term growth potential [56][57]